Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088582 · ClinicalTrials.gov registry record · Phase 2
Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT00088582 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 62 participants.
The verdict
NCT00088582, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
5 month study comparing SOM230 s.c. and Sandostatin s.c. in acromegalic patients.
Interventions
- DRUG Pasireotide (SOM230), Octreotide (Sandostatin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2004-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00088582
The ClinicalTrials.gov registry entry for NCT00088582 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pasireotide (SOM230), Octreotide (Sandostatin) is the first listed.
NCT00088582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00088582 about?
NCT00088582 is a clinical study titled "Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients". 5 month study comparing SOM230 s.c. and Sandostatin s.c. in acromegalic patients.
What is the current status of trial NCT00088582?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2004-03.
What interventions are being tested in trial NCT00088582?
The interventions under investigation include: Pasireotide (SOM230), Octreotide (Sandostatin) (DRUG).
Who is sponsoring clinical trial NCT00088582?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.